Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2010

View Archived Issues

PHY-906 beneficial when added to capecitabine in phase II pancreatic cancer trial

Perifosine plus capecitabine active in mCRC; phase III study planned

Enrollment begins into clinical trial of Alinia for acute uncomplicated influenza

PharmAthene submits White Paper for development of SparVax anthrax vaccine

Kyowa Hakko Kirin and Hisamitsu sign distribution agreement in Japan for KW-2246

Abbott and Pierre Fabre sign exclusive worldwide licensing agreement for h224G11

MK-0646 added to gemcitabine and erlotinib active in advanced pancreatic cancer

GI-4000 plus gemcitabine evaluated in ras mutation-bearing pancreas cancer

Mitaplatin targets both mitochondria and nucleus selectively in cancer cells

YM BioSciences merges with Cytopia

NeuroMed describes novel T-type voltage-gated calcium channel blockers

Novel antimicrobial agents discovered by French scientists

Kalbitor now available on U.S. market

Anadys discovers NS5B inhibitors for treatment of HCV infections

Novel NURR1/NOT ligands described by sanofi-aventis

Ariad claims new activin receptor-like kinase inhibitors for cancer therapy

FDA accepts Topica's luliconazole IND to begin trials in onychomycosis

Pearl raises funds to advance PT-003 combination bronchodilator for COPD

Pervasis receives FDA clearance for pivotal phase III Vascugel trial

Mepact for osteosarcoma reaches first market

Edoxaban enters phase III thromboembolism trial

FDA reports safety risk associated with HIV drug Videx

Cephalon enters agreement to acquire Mepha

Neuralstem treats first patient in ALS stem cell trial

Novartis reports fourth quarter and full year 2009 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...